India’s Clinical Research Revolution: NIPER Raebareli and AstraZeneca Join Hands to Strengthen 25 Clinical Trial Sites

By PharmaNation Editorial Desk | 15 October 2026

India has earned global recognition for manufacturing affordable medicines and supplying pharmaceutical products to countries across the world. From generic medicines to vaccines and complex biologics, Indian pharmaceutical companies have become essential contributors to global healthcare.

But there is another area where India has considerable untapped potential: clinical research.

A new partnership between the National Institute of Pharmaceutical Education and Research (NIPER), Raebareli, and AstraZeneca India is bringing this opportunity into focus. Announced on 14 October 2026, the collaboration aims to strengthen clinical research capabilities across 25 emerging research geographies, particularly outside the country's major metropolitan centres.

The initiative supports the Government of India's Biopharma SHAKTI vision, which includes building a national network of 1,000 clinical trial sites.

At first glance, this may appear to be another institutional collaboration. But its implications extend far beyond a memorandum of understanding. It touches pharmaceutical innovation, professional education, healthcare infrastructure, patient participation and India's long-term competitiveness in the global drug-development industry.

For PharmaNation, the bigger story is not simply that two organisations have joined hands. It is that India is taking another step towards building the infrastructure required to participate more actively in the creation of tomorrow's medicines.

1. What exactly has been announced?

NIPER Raebareli and AstraZeneca India have signed a memorandum of understanding to strengthen clinical research capabilities across 25 emerging research locations.

The partnership brings together three important elements:

• Academic expertise: NIPER Raebareli will support structured training and certification through its Centre of Excellence.

• Industry experience: AstraZeneca India will contribute clinical development expertise, training programmes, workshops and mentoring.

• Government support: The Department of Pharmaceuticals will provide direction and endorsement, aligning the programme with national clinical research priorities.

The initial programme will focus on assessing the capabilities of participating sites, identifying gaps, strengthening documentation and providing targeted training.

Particular attention will be given to research ethics, patient safety, trial feasibility, governance and preparedness for regulatory inspections.

The objective is to help participating sites develop the skills, systems and processes needed to conduct high-quality clinical research.

The programme is also intended to provide a model that could be expanded into additional regions and therapeutic areas after the initial proof-of-concept phase.

It is important to understand that this is a capacity-building initiative. The announcement does not mean that all 25 sites are already conducting trials or that every site will immediately begin recruiting patients.

2. Why does India need stronger clinical trial infrastructure?

Developing a new medicine is a lengthy and resource-intensive process.

Before a potential treatment can become an approved medicine, it must undergo appropriate scientific evaluation, including preclinical research and clinical trials where required. Clinical studies help researchers understand a medicine's safety, efficacy, dosage and potential risks in people.

Yet conducting these studies requires much more than a hospital building and a group of medical professionals.

Research sites need trained investigators, qualified study coordinators, reliable documentation systems, appropriate facilities, ethics oversight, patient-safety procedures and the ability to comply with applicable regulatory requirements.

When these capabilities are concentrated in a limited number of major cities, the country's overall research capacity can remain constrained.

Expanding research readiness into emerging locations could help address this imbalance.

It may allow more hospitals and institutions to participate in suitable research programmes, broaden the pool of trained professionals and reduce the concentration of research activity in established metropolitan centres.

However, geographical expansion alone is not enough. Every participating site must demonstrate that it can meet the required scientific, ethical and operational standards.

The real objective should not simply be more clinical trial sites, but more capable, trustworthy and research-ready sites.

3. Biopharma SHAKTI: A larger ambition behind the partnership

The NIPER–AstraZeneca collaboration is connected with the government's broader Biopharma SHAKTI initiative.

One of its stated ambitions is to establish 1,000 clinical trial sites across India as part of a stronger biopharmaceutical ecosystem.

The scale of that ambition matters.

A larger network of qualified research sites could help India accommodate more clinical studies, develop a broader pool of research professionals and improve its ability to participate in international drug-development programmes.

It could also complement the country's existing pharmaceutical manufacturing strengths.

For decades, India has demonstrated that it can manufacture medicines at scale. The next opportunity is to build equally strong capabilities in discovering, evaluating and developing new treatments.

This transition requires investment in scientific talent, clinical infrastructure, regulatory knowledge, research governance and collaboration between academia and industry.

The NIPER–AstraZeneca programme is one example of how those elements can be brought together.

Nevertheless, the 1,000-site ambition should be viewed as a broader national objective, not as a claim that the current partnership itself will establish or operationalise all 1,000 sites.

4. Why the involvement of AstraZeneca matters

AstraZeneca is a global biopharmaceutical company with experience in drug development and clinical research.

Its involvement gives the initiative access to industry expertise in areas such as research planning, trial operations, documentation, governance and site preparedness.

For emerging research centres, exposure to established clinical-development practices can be valuable. It may help institutions understand the expectations involved in participating in complex studies and working with domestic or international research sponsors.

The partnership also illustrates the value of collaboration between academic institutions and the pharmaceutical industry.

Academic institutions can contribute scientific knowledge, education and a pipeline of trained professionals. Industry partners can bring practical experience of drug development, operational systems and the requirements of multinational clinical programmes.

Government support can help align these efforts with national priorities.

Of course, a partnership announcement is only the starting point. Its long-term value will depend on the quality of implementation, the competence developed at participating sites and the extent to which those sites subsequently qualify for suitable research projects.

5. What could this mean for patients?

One of the most important potential benefits is the possibility of widening access to participation in clinical research.

When suitable clinical trials are available only at a limited number of major centres, patients living elsewhere may face substantial travel, accommodation and logistical burdens.

Developing qualified research sites in more locations could make participation more practical for some patients, depending on the conditions being studied and the locations selected.

Clinical research can also contribute to medical knowledge and, in appropriate circumstances, give eligible participants access to investigational treatments under an approved study protocol.

However, clinical trial participation is not a guarantee of receiving an effective treatment or of benefiting personally from an investigational medicine.

Trials must follow applicable ethical and regulatory requirements, including informed consent, appropriate ethics committee review and safeguards for participant welfare.

The aim must always be responsible research—not recruitment numbers at the expense of patient protection.

There is also a broader potential benefit. Stronger clinical research infrastructure can improve professional training, strengthen institutional capabilities and support the development of new treatments over time.

For patients, the real measure of success will be whether the initiative contributes to ethical, high-quality research and, ultimately, better healthcare options.

6. The opportunity for India's pharmaceutical professionals

The expansion of clinical research infrastructure could create opportunities for professionals from a range of disciplines.

Potentially relevant roles include:

• Clinical research coordinators

• Clinical research associates

• Clinical trial project managers

• Pharmacovigilance professionals

• Clinical data management specialists

• Regulatory affairs professionals

• Research quality and compliance personnel

• Biostatisticians and clinical data analysts

Pharmacy graduates, life-science graduates, medical professionals and other appropriately qualified candidates may find different entry points into this field, depending on the role's requirements.

But there is an important distinction between interest in clinical research and readiness for employment.

A short course or certificate alone does not guarantee a job. Employers may look for practical knowledge of Good Clinical Practice, research documentation, informed consent, adverse-event reporting, trial protocols, ethics requirements and applicable regulations.

For educational institutions, this creates an opportunity to strengthen training that combines theoretical knowledge with practical exposure.

For students and early-career professionals, it is a reminder that the pharmaceutical sector offers career paths beyond conventional manufacturing, quality control, medical sales and retail pharmacy.

Clinical research is one such pathway, although entry requirements and opportunities vary by position and employer.

7. What does this mean for pharmaceutical companies?

For pharmaceutical manufacturers, clinical research capacity is a strategic resource.

Companies developing new medicines need access to suitable research sites, experienced investigators and reliable study operations. A stronger domestic ecosystem could make India more capable of supporting a wider range of clinical development programmes.

This may be particularly relevant as the industry invests in innovative medicines, biologics, oncology treatments and other complex therapeutic areas.

A well-functioning clinical research ecosystem could help strengthen India's position in international development programmes and support the growth of specialised service providers.

Potentially relevant businesses include clinical research organisations, clinical data management firms, pharmacovigilance service providers, research training institutions and companies supplying suitable laboratory or clinical research equipment.

However, the partnership does not establish that any specific company will receive new contracts or that immediate commercial demand will arise at all 25 locations.

The business opportunity will depend on implementation, site qualifications, the number and type of trials conducted, sponsor requirements and the development of a sustainable research pipeline.

For smaller pharmaceutical businesses, the immediate lesson is to follow the growth of the research ecosystem and understand where future professional and service requirements may emerge.

8. The challenges India must address

Expanding clinical trial infrastructure is an important step, but several challenges will determine whether the initiative delivers meaningful results.

Quality must grow alongside capacity. Every research site needs appropriately trained personnel, dependable documentation, ethical oversight and reliable participant-safety systems.

Training must translate into practical competence. Workshops and certification programmes are valuable, but sites also need the ability to apply what they learn in real research settings.

Patient trust is essential. Transparent communication, informed consent, responsible reporting and proper handling of safety concerns are fundamental to ethical research.

Infrastructure requires sustained investment. Qualified personnel, suitable facilities, data systems and quality management processes need continuing support.

Research activity must be sustainable. Sites need opportunities to participate in suitable studies and maintain their capabilities over time rather than merely complete an initial training programme.

The success of this initiative should therefore be evaluated through measurable outcomes: improvements in site readiness, training and competency, compliance with applicable requirements, participation in suitable trials and the maintenance of high ethical standards.

PharmaNation's perspective: India must move from manufacturing medicines to building the science behind them

At PharmaNation, we see this development as part of a larger transformation taking place in India's pharmaceutical sector.

Manufacturing affordable medicines remains one of India's greatest strengths. But a globally competitive pharmaceutical industry also needs the ability to develop new treatments, conduct credible clinical research and generate evidence that meets international standards.

This requires an ecosystem in which universities, research institutes, pharmaceutical companies, hospitals, regulators and trained professionals work together.

The NIPER Raebareli–AstraZeneca partnership is a useful example of that approach. It combines academic training, industry expertise and government support to strengthen research capabilities beyond established metropolitan centres.

Its ultimate importance will depend on what happens after the announcement: whether professionals gain meaningful skills, whether participating sites become capable of conducting appropriate studies and whether patients are protected throughout the research process.

We should also be realistic. Twenty-five emerging research locations will not transform India's clinical research landscape overnight. Nor will the establishment of additional sites automatically make India a global leader.

But building a stronger ecosystem begins with developing the people, systems and institutions that make high-quality research possible.

Our view is simple: India's next pharmaceutical growth story should not be limited to how many medicines the country manufactures, but should also include how much high-quality medical knowledge it helps create.

If initiatives such as this one translate into capable research centres, stronger professional training and responsible clinical studies, they could help India take a meaningful step towards that ambition.

The announcement is a beginning. The real achievement will be a clinical research ecosystem that earns the confidence of patients, scientists, regulators and the global pharmaceutical industry.

Sources and further reading

1. Press Information Bureau, Government of India: NIPER Raebareli and AstraZeneca India partner to strengthen clinical research capabilities across 25 emerging geographies

2. Express Pharma: NIPER Raebareli and AstraZeneca India partner to expand clinical trial sites across India

3. ET Pharma: AstraZeneca and NIPER Raebareli partner to upgrade 25 clinical trial sites

Editorial disclaimer: This article is intended for pharmaceutical industry news and educational purposes. Clinical trial participation, eligibility and site readiness are subject to applicable regulatory, ethical and institutional requirements.